| 01/05/26 | 15:00:01 | 1 May 2026 | | Total Voting Rights and Admission of Shares |
| 01/05/26 | 07:05:00 | 1 May 2026 | | FDA ODAC vote on camizestrant in breast cancer |
| 01/05/26 | 07:00:07 | 1 May 2026 | | FDA ODAC recommends Truqap in prostate cancer |
| 29/04/26 | 07:00:08 | 29 Apr 2026 | | 1st Quarter Results |
| 28/04/26 | 07:00:11 | 28 Apr 2026 | | Breztri approved in the US for asthma |
| 27/04/26 | 07:00:10 | 27 Apr 2026 | | Saphnelo self-administration approved in the US |
| 23/04/26 | 07:00:06 | 23 Apr 2026 | | Directorate change |
| 21/04/26 | 07:00:08 | 21 Apr 2026 | | I CAN PhIII interim analysis met primary endpoint |
| 20/04/26 | 07:00:07 | 20 Apr 2026 | | Third tozorakimab positive Phase III in COPD |
| 09/04/26 | 17:15:01 | 9 Apr 2026 | | Result of AGM |
| 02/04/26 | 07:00:07 | 2 Apr 2026 | | Imfinzi+Imjudo improves PFS in early liver cancer |
| 01/04/26 | 15:00:00 | 1 Apr 2026 | | Total Voting Rights and Admission of Shares |
| 31/03/26 | 07:00:14 | 31 Mar 2026 | | Efzimfotase alfa Ph3 program show positive results |
| 27/03/26 | 07:00:09 | 27 Mar 2026 | | Tozorakimab met OBERON/TITANIA primary endpoints |
| 20/03/26 | 11:00:00 | 20 Mar 2026 | | Notification of Admission of Shares |
| 16/03/26 | 07:00:13 | 16 Mar 2026 | | Imfinzi approved in EU for early gastric cancer |
| 10/03/26 | 11:00:00 | 10 Mar 2026 | | Notice of AGM |
| 06/03/26 | 11:10:00 | 6 Mar 2026 | | Director/PDMR Shareholding |
| 06/03/26 | 11:05:00 | 6 Mar 2026 | | Director/PDMR Shareholding |
| 06/03/26 | 11:00:00 | 6 Mar 2026 | | Director/PDMR Shareholding |
| 02/03/26 | 15:00:00 | 2 Mar 2026 | | Total Voting Rights |
| 26/02/26 | 07:00:09 | 26 Feb 2026 | | AstraZeneca prices a $2bn bond offering |
| 25/02/26 | 07:00:02 | 25 Feb 2026 | | Filing of Form 20-F with SEC |
| 24/02/26 | 11:00:01 | 24 Feb 2026 | | Annual Financial Report |
| 24/02/26 | 07:00:08 | 24 Feb 2026 | | Directorate change |
| 20/02/26 | 07:00:08 | 20 Feb 2026 | | Fixed-duration Calquence combo approved in US |
| 10/02/26 | 07:00:09 | 10 Feb 2026 | | Final Results |
| 03/02/26 | 07:00:07 | 3 Feb 2026 | | Update on Saphnelo subcutaneous administration |
| 02/02/26 | 15:00:00 | 2 Feb 2026 | | Total Voting Rights |
| 02/02/26 | 07:05:00 | 2 Feb 2026 | | Imfinzi recommended in EU for early gastric cancer |
| 02/02/26 | 07:00:09 | 2 Feb 2026 | | AstraZeneca begins trading on NYSE |
| 30/01/26 | 07:00:06 | 30 Jan 2026 | | AstraZeneca agrees obesity and T2D deal with CSPC |
| 29/01/26 | 09:51:51 | 29 Jan 2026 | | AstraZeneca invests $15bn in China through 2030 |
| 20/01/26 | 07:00:01 | 20 Jan 2026 | | AstraZeneca to complete direct listing on NYSE |
| 08/01/26 | 07:00:08 | 8 Jan 2026 | | AZN new Head of Investor Relations Joris Silon |
| 02/01/26 | 15:00:00 | 2 Jan 2026 | | Total Voting Rights |
| 22/12/25 | 11:00:00 | 22 Dec 2025 | | Director/PDMR Shareholding |
| 22/12/25 | 07:30:00 | 22 Dec 2025 | | Enhertu granted BTD for post-neoadjuvant early BC |
| 22/12/25 | 07:00:08 | 22 Dec 2025 | | Update on LATIFY Phase III trial of ceralasertib |
| 19/12/25 | 11:00:00 | 19 Dec 2025 | | Director/PDMR Shareholding |
| 16/12/25 | 07:05:00 | 16 Dec 2025 | | Subcutaneous Saphnelo approved in EU |
| 16/12/25 | 07:00:08 | 16 Dec 2025 | | Enhertu approved in US for 1L HER2+ metastatic BC |
| 04/12/25 | 15:00:00 | 4 Dec 2025 | | Holding(s) in Company |
| 01/12/25 | 15:05:00 | 1 Dec 2025 | | Block listing Interim Review |
| 01/12/25 | 15:00:00 | 1 Dec 2025 | | Total Voting Rights |
| 26/11/25 | 07:00:14 | 26 Nov 2025 | | Imfinzi approved in US for early gastric cancer |
| 24/11/25 | 07:00:11 | 24 Nov 2025 | | AstraZeneca manufacturing investment in Maryland |
| 20/11/25 | 07:00:15 | 20 Nov 2025 | | Koselugo (selumetinib) approved in the US |
| 17/11/25 | 15:00:01 | 17 Nov 2025 | | Holding(s) in Company |
| 14/11/25 | 11:00:00 | 14 Nov 2025 | | Director/PDMR Shareholding |
